The prognostic significance of miR-17-5p and miR-20a-5p in prostate cancer

Prostate cancer accounts for extensive mortality and is the second most frequent cancer type occurring in men, acknowledged as a severe health problem globally. In Norway, Prostate cancer is the most common form of cancer in men, and around 5.000 patients are diagnosed each year. Using in situ hybridization, we examined the in situ tissue distribution of miR-17-5p and miR-20a-5p in prostate cancer tissue and their potential functions as biomarkers, and assessed their prognostic value from our cohort of 535 prostate cancer patients. We retrospectively evaluated the prognostic impact of marker expression in the clinical outcome Biochemical failure, Clinical failure, and Prostate cancer death by utilizing survival analyses. In addition, we correlated the microRNAs miR-17-5p and miR-20a-5p with the proliferation marker Ki-67. Reducing over-treatment in PCa patients have for many years been an ongoing concern. This controversy underlines the need for more personalized diagnosis and treatment of these patients, whereas miRNAs as biomarkers proposes as promising candidates. miR-17-5p and miR-20a-5p, which are members of the miR-17-92 cluster that are known to act as oncomiRs, may have potential as prognostic biomarkers in prostate cancer, and a possible value in future treatment of prostate cancer